A5067726122- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Head and Neck Cancer Studies
- Lung Cancer Diagnosis and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Cancer Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Ear and Head Tumors
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Melanoma and MAPK Pathways
- Cancer Cells and Metastasis
- Liver physiology and pathology
- Viral-associated cancers and disorders
- Cell Adhesion Molecules Research
- Radiomics and Machine Learning in Medical Imaging
- BRCA gene mutations in cancer
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- PARP inhibition in cancer therapy
City Of Hope National Medical Center
2019-2024
City of Hope
2018-2024
Weatherford College
2020
KRAS mutations reported in non-small cell lung cancer (NSCLC) represent a significant percentage of patients diagnosed with NSCLC. However, there still remains no therapeutic option designed to target KRAS. In an era immunotherapy as dominant treatment metastatic NSCLC, the role in.mutated is not clear.Eligible NSCLC and found have mutation were identified institutional database. Demographic, clinical, molecular data was collected analyzed.A total 60 for this retrospective analysis. Majority...
The usefulness of circulating tumor DNA (ctDNA) in detecting mutations and monitoring treatment response has not been well studied beyond a few actionable biomarkers non-small cell lung cancer (NSCLC).
EGFR-mutated lung adenocarcinoma patients who received tyrosine kinase inhibitors (TKIs) may initially respond to therapy, but over time, resistance eventually occurs. In a small population (5-10%), these can have histological transformation SCLC. Nine with transformed SCLC were evaluated at City of Hope. Patient clinical and pathology data, including multiple next-generation sequencing (NGS) results, therapies, histology, outcomes, collected across time points. Descriptive statistics...
Background The study summarizes the potential use of immunotherapy for BRAF- mutated papillary thyroid cancer (PTC) by analyzing immune profile City Hope PTC patient samples and comparing them to dataset available in TCGA database. Materials methods cases with formalin-fixed paraffin-embedded archived tumor tissue were identified. RNA was extracted from analyzed NanoString evaluate their gene expression profile. Immunohistochemistry used determine suppressive genes lymphocytic infiltration...
BackgroundThe survival advantage of induction chemotherapy (IC) followed by locoregional treatment is controversial in locally advanced head and neck squamous cell carcinoma (LAHNSCC). We previously showed feasibility safety cetuximab-based IC (paclitaxel/carboplatin/cetuximab—PCC, docetaxel/cisplatin/5-fluorouracil/cetuximab—C-TPF) local therapy LAHNSCC. The primary end point this phase II clinical trial with randomization to PCC C-TPF combined patients LAHNSCC stratified human...
Patients reporting high PD-L1 expression have shown to respond well immunotherapy; however, some patients develop hyperprogressive disease upon initiation of immune checkpoint inhibitors. We report a patient with lung cancer and 100% who developed while treated pembrolizumab responded salvage chemotherapy carboplatin pemetrexed.A 66-year-old African American female 25-pack year smoking history, diabetes mellitus type 2, essential thrombocytosis, history papillary thyroid carcinoma relapsed...
Metastasis continues to be the primary cause of all cancer-related deaths despite recent advancements in cancer treatments. To evaluate role mutations overall survival (OS) and treatment outcomes, we analyzed 957 metastatic patients with seven major types who had available molecular testing results a FoundationOne CDx® panel. The most prevalent genes somatic were TP53, KRAS, APC, LRP1B. In this analysis, these mutation frequencies higher than publicly datasets. We identified that mutually...
Omic-informed therapy is being used more frequently for patients with non-small-cell lung cancer (NSCLC) treated on the basis of evidence-based decision-making. However, there a lack standardized framework to evaluate those decisions and understand association between omics-based management strategies survival among patients. Therefore, we compared outcomes adenocarcinoma who received omics-driven targeted versus standard therapeutic options.This was retrospective study advanced NSCLC (N =...
Immune-related adverse events (IRAEs) are a common yet problematic phenomenon in patients who treated with immune checkpoint inhibitors (ICIs). Current research efforts have explored the exact pathophysiology of IRAEs clinical setting. However, rare subset that is less highlighted and may cause detrimental effects hematological (heme-IRAEs). Of note, immune-induced eosinophilia itself heme-IRAE worthy further investigation. In this report, we present two cases advanced staged non-small cell...
Oncology has become more reliant on new testing methods and a greater use of electronic medical records, which provide plethora information available to physicians researchers. However, take advantage vital clinical research data for precision medicine, we must initially make an effort create infrastructure the collection, storage, utilization this with uniquely designed disease-specific registries that could support collection large number patients.In study, perform in-depth analysis series...
Salivary gland tumors (SGTs) are heterogeneous that range from benign masses to aggressive high-grade carcinomas with distant metastatic potential and limited response chemotherapy. Mucoepidermoid carcinoma (MEC) accounts for 10% of SGTs has a poor prognosis. In this research report, we describe two cases MECs prolonged immune checkpoint inhibitor pembrolizumab. Case 1 presented left neck mass, biopsy the parotid mass revealed MEC. The patient underwent surgical resection adjuvant...
Non-small cell lung cancer is a devastating disease and with the advent of targeted therapies molecular testing, decision-making process has become complex. While established guidelines pathways offer some guidance, they are difficult to utilize in busy community practice not always implemented community. The rationale study was identify cohort patients adenocarcinoma at City Hope site (n = 11) their case studies develop framework utilizing fast-and-frugal tree (FFT) heuristics. Most had...
Heuristics and the application of fast-and-frugal trees may play a role in establishing clinical decision-making framework for value-based oncology. We determined whether oncology can be structured heuristically based on timeline patient's treatment, intuition, evidence-based medicine. A group 20 patients with advanced non-small cell lung cancer (NSCLC) were enrolled into study extensive treatment analysis sequential decision-making. The genomic data allowed us to evaluate methodology...
<h3>Background</h3> Immune checkpoint inhibitors (ICIs) have become an effective treatment for advanced cancers, but their role in treating papillary thyroid cancer (PTC) remains uncertain. Although CD274 is present trials with shown limited success, overall response rate (ORR) of just 3.8%. These results suggest that factors beyond CD274, including other genes or signaling pathways, may contribute to the poor immunotherapy. We aimed investigate impact BRAF mutations and downstream on...
Lung cancer patients undergoing systemic treatment with immune checkpoint inhibitors (ICIs) can lead to severe immune-related adverse events (irAEs) that may warrant immediate hospitalization. Patients thoracic malignancies hospitalized at City of Hope while ICIs were identified. Pathology and available next-generation sequencing (NGS) data, including the programmed death-ligand 1 (PD-L1) status clinical information, hospitalizations, invasive procedures, occurrence irAEs, collected....